DSM Pharmaceutical Products today announced that it has made a manufacturing alliance with Galenix, Saint Jean D'Illac, France, where DSM will be the preferred commercial scale manufacturing partner for Galenix commercial products on a global basis.
DSM and Galenix will collaborate on business development opportunities co-marketing Galenix drug delivery technologies, based on the strength of Galenix in drug product development and clinical services and DSM in process development, scale up and commercial scale pharmaceutical manufacturing.
Pieter de Geus, Senior Vice President, R&D stated, "These innovative drug delivery technologies enhance our offering in the field of pharmaceutical development services and complement our portfolio of drug delivery technologies. The collaboration with Galenix clearly demonstrates DSM's commitment to bringing improved drug delivery to markets globally."
Hans Engels, President of DSM Pharmaceuticals, Inc. commented, "The alliance brings out the best of both parties. Combining innovative formulations with flawless transition into commercial products creates an attractive value proposition for any drug company."
Jerome Besse, CEO of Galenix concurred with the DSM comments, and further added, "This is truly a win-win situation. Galenix is privileged in working with DSM to generate value for our customers. The partnership fits with our strategic intention of expanding service offerings to the North America market, and also with DSM's expansion of sales & marketing focus in Europe."
No financial terms were disclosed.
Stem-cell implants restore vision in patients with corneal stem cell deficiency